|
|
Ariad Pharmaceuticals Incorporated - Comparative Business Analysis Snapshot
Business Description
Ariad Pharmaceuticals Incorporated. The Group's principal activities are the discovery and development of medicines that treat cancer by regulating cell signaling with small molecules. The Group's lead product candidate, AP23573, is in multiple Phase 1 and Phase 2 clinical trials and is used for the treatment of solid tumors and hematologic cancers. In the Group's bone-targeted mTOR inhibitor program, it is developing a novel and potent follow-on product candidate analogous to AP23573, which treats bone cancers and block the spread of bone sarcomas. In the Group's oncogenic kinase inhibitor program, it is developing potent inhibitors of enzymes involved in the growth, proliferation and spread of cancer. The Group operates in the United States.
Competitor Analysis
This analysis compares Ariad Pharmaceuticals Incorporated with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
|
|
|
|
